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Abstract
Group B saponins, the predominant form of saponins in heat-treated soy products, have
been shown to possess hypocholesterolemic, antimutagenic, and anticarcinogenic properties.
Previous studies have evaluated crude mixtures of soyasaponins, but studies evaluating a single
purified soyasaponin as an anticarcinogenic agent are limited. The goal of this study is to
examine the effects of purified soyasaponins I and III as well as their aglycone form,
soyasapogenol B, as anticarcinogenic agents on the human colon adenocarcinoma cell line Caco2. Experiments were conducted to determine the effects of purified soyasaponins on cell
proliferation, Protein Kinase C (PKC) activity, and cell morphology in cultures of Caco-2 cells.
Treatment of cells with soyasaponins I and III at concentrations of 300–900 ppm significantly
reduced viable cell numbers after 48 and 72 hours of exposure by 10-35% (p<0.05).
Soyasapogenol B at a concentration of 100 and 150 ppm significantly reduced viable cell
numbers after 24 hours by 15 and 62%, respectively (p<0.05). Cell morphology changes
demonstrated that as concentrations and lipophilicity of soyasaponins increased, cell membranes
became rougher and more irregular. Treatment of cells for 72 hours significantly reduced the
amount of PKC activity by 9-40% (p<0.05). Results indicate that purified soyasaponins I, III
and soyasapogenol B, at physiologically relevant doses, can suppress Caco-2 colon cancer cell
proliferation. These findings suggest that purified group B soyasaponins and their final
metabolite soyasapogenol B may be a colon-cancer suppressive component of soy that warrants
further examination as a potential nutraceutical or functional food.
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Chapter I. Introduction

Colorectal Cancer (CRC) is the third most commonly diagnosed cancer and is the second
leading cause of mortality in the U.S., causing an estimated 49,920 deaths in 2009 in addition to
the 146,970 new cases that were also reported [1]. According to the American Cancer Society,
the lifetime risk of being diagnosed with cancer of the colon or rectum is 5.5% for men and 5.1%
for women in the US. Remarkably, only 20-25% of CRC cases occur among individuals with a
family history of CRC or a predisposing condition and the remaining 75% of cases occur in
people without these risk factors [2]. Prevalence of CRC has been declining in the U.S. since
1998, however, worldwide incidence and deaths from colon cancer are generally increasing,
especially in the developed world and urban areas of developing countries [3]. North America,
Australia/New Zealand, Western and Eastern Europe have the highest colon cancer rates. These
areas account for over 63% of incidence worldwide [3]. In what used to be considered low risk
areas like Central and South America, Asia, and Africa, rates are beginning to increase as well
[4]. Because of these large geographic differences, it is likely that a number of factors affect the
likelihood of developing colon cancer; among them being heredity, sex, age, race, pre-existing
conditions, lifestyle, and diet.
The goal of this study was to evaluate the effects of the predominant soyasaponin in heat
treated soy products (soyasaponin I) and its two predominant metabolites (soyasaponin III and
soyasapogenol B) on human colon cancer cells. The hypothesis of this study is that purified
soyasaponin I and its metabolites are more effective at suppressing colon cancer cell growth than
crude mixtures of soyasaponins. The objectives of this study were 1) to investigate what
soyasaponins are most effective at inhibiting colon cancer cell growth and 2) to determine at
what concentration they are most potent. To accomplish these objectives, cell viability and
1

protein kinase C (PKC) were measured and cell morphology changes were observed. The effects
of soy and other topics important to the development of colon cancer will be addressed in the
following review.
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Chapter II. Review of Literature
Colon Cancer
Colon cancer is the product of both environmental and hereditary factors that have yet to
be completely identified or understood. Data from numerous epidemiological studies indicate
diet and soy consumption as important factors contributing to the risk and development of certain
types of cancer, particularly breast, prostate, and colon. Investigations into the relationship
between cancer and soy intake has led scientists to conclude that phytochemicals within soy are
responsible for these effects, and that the mechanisms by which different phytochemicals exert
their effects are as varied as the phytochemicals themselves.

Pathogenesis of Colon Cancer
The development of colon cancer is a multistep process that is a consequence of a closely
tied, but not fully understood, interaction between genetic and environmental factors [5]. A
defining characteristic of colon cancer is the step-wise progression from normal colonic tissue to
the malignant cell growth that is associated with chronological molecular deviations leading to
tumor development [6]. It was discovered in the 1990s that the accumulation of activated
oncogenes and the inactivation of tumor-suppressor genes that the colorectal epithelium
progresses from a normal phenotype to one that is hyperproliferative and malignant in nature [5].
Sporadic CRC is one of the most common malignancies worldwide; because of this, there
has been much research done in order to elucidate the underlying causes. This has revealed
complex processes that lend to the generation of the required mutations and identification of
various groups of target genes that govern the biological behaviors which are seen in tumor cells
[7].
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As mentioned above, colon cancer development is a multi-stage process in which altered
cells progress to precancerous lesions such as adenomatous polyps, that if given enough time,
will develop into carcinomas. The gastrointestinal epithelium is a complex microenvironment
that is composed of at least four different interconnected cell types. In addition to other cell
types, absorptive enterocytes, goblet cells, Paneth cells, and enteroendocrine cells are
characterized by a tightly-regulated succession of cell proliferation, maturation, differentiation,
and apoptosis [7]. The genetic model proposed by Fearon and Vogelstein [5] indicates that a
hyperproliferative colonic epithelium is the first step towards colon cancer development.
Populations that are at high risk (advanced age, genetically predisposed, presence of
adenomatous polyps, or familial adenomatous polyposi [FAP]) have been shown to have
increased mucosal cell proliferation throughout their colon [7]. Gene mutations and/or deletions
accompany the promotion of a hyperproliferative normal crypt to an adenoma. It is during this
initiation stage that the gatekeeper genes which are responsible for the control of cell
proliferation, differentiation, migration, and apoptosis within the colonic mucosa are altered [811]. The transformation to a cancerous state is often associated with the loss of several more
genes including those that prevent cells with damaged DNA from progressing to the S-phase of
the cell cycle, which thereby makes them responsible for the repair of DNA before allowing
another round of cell division [12-14].
Increased proliferation is seen in adenomas when compared to normal epithelium, and in
addition to this, a shift in the proliferation toward the luminal surface of the epithelium occurs in
adenomas as well as aberrant crypt foci (ACF) [7, 15]. Indicators of the increased colorectal
crypt cell proliferation and of the expansion of the proliferative zone toward the luminal surface
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of the crypts have been identified. These indicators are of interest because they are biomarkers of
future risk for the development of colon tumors [5, 16, 17].
ACF are induced by colon specific carcinogens in a dose dependant manner, evolve from
one altered crypt, and exhibit preneoplastic features (dysplasia, abnormal cell proliferation
patterns, and various gene mutations) [18]. ACF have shown to be larger than normal crypts,
show increased branching and proliferation, and reportedly contain cells which demonstrate a
variety of changes that indicate they are at an early stage in the process of cancer development
[19-21]. In addition to rodent models, ACF have been described in human colonic mucosa as
well [22-25]. Perhaps more importantly is the fact that they are predictors of tumor outcome and
are a valuable tool for quantifying risk [15, 18, 26]. It is because of these characteristics that
ACF are of concern to researchers interested in the early morphological changes which take
place in the development of tumors or adenocarcinomas.

Epidemiology
Numerous studies and reports have shown that cancer is a widespread disease, and
according to the World Health Organization (WHO), was responsible for 7.9 million deaths in
2007. Whereas the universality of cancer is not disputed, the distribution of certain cancer types
and target organs is distributed unequally among different countries, those who live in urban
areas as compared to rural areas, people of different ethnicities, race, socioeconomic status, and
sex [27]. Such variations are inevitably due to genetic variations, environmental factors, and
diet.
According to the International Agency for Research on Cancer, worldwide rates of CRC
have variances of up to 25-fold, the highest rates being found in the developed world and the
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lowest in India. However, even within this one country, there are differences in CRC incidence
between populations, such as the increased rates of the Westernized Parsi and the strictly
vegetarian Janists [28]. Supporting evidence for this trend can be seen in migrant studies, such
as Japan to USA and Eastern Europe to North America. When studying the change in CRC rates
among immigrants, when populations moved from low- to high-risk areas, the connection to
environmental factors becomes quite evident; the rate of CRC increases rapidly, indicating that
dietary as well as other environmental factors contribute a great deal to risk development [29,
30]. Proof of this can be seen in Japanese individuals who were born in the USA now having
higher rates than those of US whites, and the rates of colon cancer of Japanese living in Hawaii
and Los Angeles are among the highest in the world [31]. Migrant studies have also shown
incidence rates of migrants and their descendants reaching that of the host country, sometimes
even within one generation [4]. These studies demonstrate how a change from a plant-based diet
to a Westernized diet affects the etiology of colorectal malignancies and shows a clear
relationship between diet and cancer risk, thereby making it of considerable interest to those in
the medical field as well as nutrition researchers.

Diet and Colon Cancer Relationship
Genetics and environmental factors can only explain so much, considering that genetic
factors alone are only believed to explain roughly 5% of all cancers [32]. With that in mind, it is
estimated that approximately 66-75% of CRC could be prevented by proper diet and lifestyle
changes [4]. The role of diet in cancer prevention has been documented, but the exact dietary
components that have greatest effect on risk have been difficult to pinpoint. The difficulty in
showing direct relationships between dietary components and their corresponding cancer risk is
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due in large part to inconsistent data from community- and population-based studies [32].
Factors contributing to these inconsistencies include the lack of an accurate measurement of
types of dietary fat in the foods of the population under investigation as well as inconsistent
questionnaires intended to quantify fruit and vegetable intake [17, 33]. Evidence from numerous
cohort and case-control studies has shown that there is an inverse relationship between diets rich
in fruits and vegetables and cancer risk. Different factors responsible for this finding include:
fiber intake, micronutrients (carotenoids, ascorbate, and folate among others), and
phytochemicals [17].
Although no strong correlation between any one particular food and the increased risk of
colon cancer can be made, there have been many epidemiological studies which conclude that
the consumption of soy foods may contribute to lower rates of various cancers, namely colon,
breast, and prostate cancer in countries such as China and Japan [34-36]. Japan has been heavily
studied for their plant-based diet, specifically their consumption of soy and soy products. There
has been considerable interest in the soy consumption of this country because of their lowerthan-average disease rates and the belief that soy has health benefits that go beyond the nutrients
it provides. Several epidemiological studies [37-40] have been conducted in order to determine
soy intake and related disease risk or incidence of the study populations. Soy is a rich source of
phytochemicals such as isoflavones and saponins. Phytochemicals are non-nutrient secondary
metabolites of plants that are biologically active. Of which, some have been shown to possess
various activities that are beneficial to health when they are consumed as part of the diet.
Because isoflavones have been so intensely investigated for their potential health benefits and
because saponins are a major group of phytochemicals in soy, this review and subsequent
research project will focus on soyasaponins.
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Soyasaponins
Saponins are a group of amphiphilic and structurally complex glycosides that consist of
one or more oligosaccharide moieties linked to a triterpenoid or steroidal aglycone ring structure
(sapogenol). These can be found in a variety of plants such as ginseng, Quillaja, Gypsophila,
and soybeans. Their surface-active properties, which are a result of their hydrophilic sugars and
lipophilic sapogenol, are the source of the name saponin, which comes from the Latin word for
soap “sapo” [41]. It is important to note that the bioactivity of saponins vary depending on their
source and chemical make-up [42, 43], which includes variances between ring structures as well
as number and type of carbohydrate moieties.

Chemistry of Soyasaponins
Soyasaponins, as their name implies, are saponins from soybean. Soyasaponins vary in
the composition of their soyasapogenol as well as the number, type, and point(s) of attachment of
their sugar moieties to the soyasapogenol (Figure 1). Originally, it was thought there were up to
five different soyasapogenols, however, as research advanced it was determined that
soyasapogenols C, D, and E were artifacts of hydrolysis and that there are two specific
pentacyclic triterpenoid sapogenols to which the sugar moieties attach: soyasapogenol A and
soyasapogenol B [44-47] (Figure 2). A number of different sugar moieties exist, including Larabinose and L-rhamnose which are linked α-glycosidically, and D-glucose, D-xylose, Dgalactose, and D-glucuronic acid which are β-glycosidically-linked [41]. These sugar moieties
are attached to position 3 of the triterpenoid aglycone by an ether linkage. Because group B
soyasaponins are the predominant form in soy and soy products, they will be the focus of this
literature review and subsequent research.
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Figure 1. Soyasaponin structure and nomenclature, adapted from Kudou et al. [49]

DDMP
αg
βg
βa
γg
γa

Non-DDMP
V
I
II
III
IV

R1
CH2OH
CH2OH
H
CH2OH
H

R2
α-L-Rhamnose
Β-D-Glucose
α-L-Rhamnose
H
H

It appears that the group B soyasaponins ((αg, βg, βa, γg and γa)
a) exist in the intact plant
tissue as conjugates of 2,3-dihydro
dihydro-2,5- dihydroxy-6-methyl-4H-pyran-4-one
one (DDMP) at the 22
hydroxyl position and are considered to be the genuine form of saponin [48].
[

The bond

connecting the DDMP molecule to the soyasaponin is easily degraded, resulting in the formation
of the non-DDMP
DDMP group B soyasaponins (V, I, II, III, and IV), which explains their
predominance in heat treated soy products [48, 49].. The degradation of the DDMP-conjugated
DDMP
soyasaponin yields maltol and the corresponding non-DDMP-conjugated
conjugated soyasaponin. This
means DDMP group B soyasaponin αg → non-DDMP group B soyasaponin V, βg
β → I, βa→II,
γg→III, and γa→IV.
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Figure 2. Soyasapogenol A and B chemical structures

Aglycone
Sapogenol A
Sapogenol B

R1
OH
H

R2
OH
OH

Bioactivity of Soyasaponins
Evidence from numerous studies indicates that soyasaponins have a wide variety of
physiological effects. Antioxidant activity of soyasaponins, namely the DDMP-conjugates has
been evaluated in their ability to act as free radical scavengers because of their ability to donate
an electron from its double bond moiety [50-53]. The in vivo hypocholesterolemic effects of
soyasaponins have been evaluated as well [54, 55]. Other in vitro studies have demonstrated
hepatoprotective [56-58], antiviral [59-61], anti-inflammatory [61], and immune-enhancing
properties [62]. Because of their unique structure and amphiphilic nature, soyasaponins have
been studied for a wide variety of biological effects; however, much of the interest in
soyasaponins lies in their anti-carcinogenic properties.

Anti-Carcinogenic Activity in Tissue Culture and Animals
There have been multiple in vitro studies [63-75] and one in vivo study [76] conducted to
investigate the anti-mutagenic or anti-carcinogenic properties of soyasaponins. It is from these
studies that we have gained more of an understanding as to how soyasaponins may suppress the
growth of cancer cells. Through in vitro studies, the effect a known compound has on a specific
10

type of cell and cell process (i.e. apoptosis, differentiation, and proliferation) can be closely
monitored and the molecular pathway can be elucidated, additionally, the overall effect on health
and organ systems can be observed in animal studies.

In Vitro Studies
There have been numerous studies which utilized different soyasaponins and
soyasapogenols at various concentrations and have displayed anticarcinogenic properties in
several different carcinoma cell lines [63-66, 68, 71-75, 77]. The results of these studies are
summarized in Table 1. From the studies listed, it is apparent that there are several factors that
contribute to the observed effects of soyasaponins and their sapogenol on cancer cell lines. The
first of these factors is the testing material itself. The majority of these studies utilized a crude
mixture of all group-A and group-B soyasaponins or just group-B soyasaponins, whereas others
used semi-purified individual soyasaponins. The use of crude extracts makes it difficult to match
a result observed in the cells to a molecular action of a specific soyasaponin. Because of this,
studies with purified soyasaponins are very important for identifying how purified soyasaponins
affect bioactivity and the mechanisms involved in cell growth and viability. The second factor is
the dose. Concentrations ranging from 6.25-2400 ppm have been used in various studies
yielding different degrees and types of cell suppression. The third factor affecting results is the
incubation time. Most studies monitor cell growth and viability at 24, 48, and 72 h, however this
can vary from as little as 4 hours [74] to as long as 5 days [63]. Such variances are bound to yield
different results.
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Table 1. Summary of anticarcinogenic activities of soyasaponins and their sapogenol
Type of
Saponin
Group-B
soyasaponin
mixture

Cell
Line
HCT-15

Concentration

Observation

Mechanism

Reference

150-600 ppm

Dose-dependent
reduction in cell
growth and viability
after 48 h.

Formation of
cytoplasmic
vesicles and
deformation of
plasma and nuclear
membrane.

[66]

Group-B
soyasaponin
mixture

HCT-15

150-600 ppm

Dose-dependent
reduction in growth
and viability after
48 h. Growth
completely
inhibited at 24 h
with 300 and 600
ppm.

Unknown, possibly
due to saponin-cell
membrane
interactions

[67]

Group-B
soyasaponin
mixture

HT-29

150-600 ppm

Dose-dependent
reduction in cell
growth when
maintained for 72 h.

Suppression of
PKC activity and
induction of
differentiation

[65]

Soyasaponin I
(89% pure)

HT-29

6.25, 12.5, 25,
50 ppm

Saponin I had no
inhibitory effect on
cell growth

The suppression of
cell growth is
intensified with the
increase in
lipophilicity.
(Sapogenol B >
Saponin III >
Saponin I)

[73]

Down regulation of
COX-2 and PKC
expression

[64]

Soyasaponin III
(86% pure)

Saponin III
suppresses growth
at 50 ppm after 72
h.

Soyasapogenol
B (93% pure)

Sapogenol B shows
dose-dependent
suppression from 650 ppm after 72 h.

Group-B
soyasaponin
mixture

HT-29

150-600 ppm

Dose-dependent
reduction in cell
growth at all
concentrations after
72 h.
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Table 1. (continued)
Type of
Saponin
Soyasaponin I

Cell
Line
Caco-2

Soyasapogenol
B

Concentration

Observation

Soyasaponin I
470-2800 ppm

Soyasaponin I
had no effect on
cell viability

Soyasapogenol
B
230-1375 ppm

Mechanism

Reference

unknown

[74]

Soyasapogenol
B significantly
reduced cell
viability at 230
and 1375 ppm
after 4 h

Group-B
soyasaponin
mixture

HCT-15

25-500 ppm

Suppress
proliferation
dosedependently and
induced
macroautophagy
at 100 ppm after
24 h

Cells delayed in
S-phase of cell
cycle.

[71]

Group-B
soyasaponin
mixture

Caco-2

25-100 ppm

Group-B
soyasaponins
had no effect on
cell growth.

No mechanism
offered.
However, no
negative effects
on cell
morphology were
observed.

[77]

Induction of cell
differentiation at
lower
concentrations
and induction of
type II
autophagic death
at higher
concentrations

[63]

Soyasapogenol
B

Group-B
soyasaponin
mixture

Soyasapogenol
B significantly
reduced cell
growth at 25, 50,
and 100 ppm
HT-29

150-2400 ppm

Decreased cell
viability in dosedependent
manner,
suppressed PKC
activity, and
increased AP
activity
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Proposed Mechanism of Anticarcinogenic Properties of Soyasaponins and
Soyasapogenols In Vitro
From published research, it appears as though there may be more than one mechanism of
action for the anticarcinogenic effects of soyasaponins. With regard to human colon cancer cell
line studies, there have been two widely proposed mechanisms by which soyasaponins elicit their
effects. One is the induction of cell differentiation through increases in alkaline phosphatase
(AP) and reductions in protein kinase C (PKC) [63-65], and the other is induction of type II
autophagic death or macroautophagy [63, 71]. PKC is a marker for cell proliferation and its
activity increases as cells undergo the proliferation process. AP is used as a biomarker to
indicate differentiation in cells. Studies which monitored the activity of AP and PKC showed
that treatment with saponins at lower concentrations were able to induce cell differentiation.
Type II autophagic death, or macroautophagy has been observed in two different studies [63, 71]
through scanning electron microscopy (SEM), to observe differences in cell morphology, and
transmission electron microscopy (TEM), to observe differences in intracellular morphology.
In addition to the changes in cellular morphology visible by SEM, under TEM observation,
vacuoles appeared in the cells that had been treated with higher concentrations of soyasaponins.
This observation was also seen in the study by Ellington et al. [71] along with decreased cellular
density, the absence of mitochondria, and prominent vacuoles containing degraded cellular
material. All of these observations indicate that treatment of cells with group-B soyasaponins
does not directly induce apoptosis, but instead induces morphological changes supportive of type
II autophagic cell death.
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In Vivo Studies
Studies conducted which utilized soy components known to contain both soyasaponins
and isoflavones have decreased chemically induced colon carcinogenesis in mice and [78, 79].
However, there have been conflicting results when trying to identify specifically which
compounds reduce carcinogenesis in animal models. Soy protein isolate was shown to be
protective against azoxymethane (AOM) induced tumors in rats [79]. Isoflavones and
soyasaponins were both present in the soy protein, so there can be no definite answer as to which
compound was effective in preventing the tumors. Thiagarajan et al. [78] demonstrated that soy
flour and soy flakes, products known to include soyasaponins and isoflavones, as well as the
isoflavone genistein significantly reduced the incidence and multiplicity of ACF in AOM treated
rats. They also demonstrated that ethanol washed soy protein concentrate, a product devoid of
soyasaponins, did not reduce the incidence or multiplicity of ACF in these rats. Conflicting
evidence from a study conducted by Rao et al. [80] demonstrated that a diet supplemented with
250 ppm of genistein enhanced carcinogenesis in AOM treated male rats. Because of conflicting
results regarding isoflavones, genestin in particular, and because ethanol washed soy does not
reduce carcinogenesis in animal models, it appears as though soyasaponins may be responsible
for the effects seen in the studies which utilized soy protein or soy flour.
The in vivo study mentioned earlier by Koratkar and Rao [76] evaluated the
anticarcinogenic effect of a soyasaponin extract containing 8-10 different soyasaponins on an
AOM treated CF-1 mouse model. AOM is a colon cancer specific carcinogen intended to initiate
cancer in rodents which rarely develop sporadic cancer in nature. One week postinitiation, the
mice were placed on a basal AIN-76 diet containing no saponins or one containing 3%
soyasaponin by weight. At the end of the 14 week feeding period, the mice were sacrificed and
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colons were evaluated for ACF using the method from Bird et al. [18]. In this study, the
consumption of soyasaponins significantly reduced the incidence of ACF as well as the number
of aberrant crypts per focus. The authors suggest that the soyasaponins had undergone microbial
hydrolysis of their sugar moieties in the cecum and large intestine, and that because the
soyasaponins are not absorbed from the gastrointestinal tract it is likely that they can interact
with free or membrane-bound sterols as well as bile acids. This hypothesis agrees with research
evaluating the interaction of soyasaponins with bile acids [81-84] and research evaluating the
hypocholesterolemic effect of soyasaponins [54, 55].

Proposed Mechanism of Soyasaponins in the Prevention of Colon Cancer In Vivo
Within animal models, the ability of soyasaponins and their soyasapogenol to bind with
bile acids is widely accepted as the mechanism by which they elicit cholesterol-lowering and
anti-colon cancer effects. Bile acids are the major end products of cholesterol metabolism and
are formed in the liver. From the liver, they are concentrated and stored in the gallbladder where
they can be secreted into the small intestine to act as cholesterol solubilizing agents and aid in
lipid digestion and absorption. Under normal conditions, approximately 95% of bile acids
passing through the ileum are reabsorbed through the portal vein and return to the liver to be
secreted again as part of the enterohepatic circulation.
Primary bile acids which have been transformed to secondary bile acids have been
implicated in the carcinogenic process. These amphiphilic molecules are formed in the large
intestine by the enzymatic deconjugation and dehydroxylation of primary bile acids by anaerobic
colonic bacteria [85]. Secondary bile acids trigger a cascade of events within the colon, each
leading to another event potentially resulting in cancer development.
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The secondary bile acids, like lithocholic acid, can be co-mutagenic due to their ability to
cause DNA strand breaks [86, 87]. Additionally, they are cytotoxic and are disruptive to the
colonic mucosal cell membrane integrity [88]. The resulting cell loss stimulates a response by
the body to increase cellular proliferation in an attempt to compensate. There is also evidence of
a direct stimulatory effect on proliferation mediated by protein kinase C (PKC) activation in the
colonic cells [89]. In many cell systems the activation of PKC can lead to the induction of
proteins that form transcription factor AP-1 [89]. Bile acids and lipid components in the aqueous
fraction of the stool can activate AP-1, whose activation has been associated with promotion of
neoplastic transformation [90].
Colon cancer is rarely the result of one single event; typically, it is the final outcome of
the interplay between a number of different genetic and environmental variables. One example of
this would be the inhibition of apoptosis by deregulation of a number of oncogenes, which could
result in colonal expansion. Incidentally, one of the secondary bile acids, deoxycholic acid
(DCA) was an effective inducer of apoptosis [88, 91-93]. The enhanced apoptosis by bile acids
might be the result of their DNA-damaging properties or their damaging effects on the colonic
mucosa.
The anti colon cancer properties of soyasaponins in vivo are a result of their ability to
bind with primary bile acids and prevent the formation of secondary bile acids. As mentioned
before, approximately 95% of bile acids and salts that are secreted into the duodenum are
reabsorbed. This allows 2-5% of primary bile acids to escape to the colon and can amount to
approximately 20% of the bile acid pool over the course of 6-12 enterohepatic circulations that
occur daily. The ability of soyasaponins to bind bile acids within the small intestine and their
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soyasapogenol binding to bile acids in the colon could result in a reduction of primary bile acids
that are metabolized by the colonic microflora into secondary bile acids.
From the previously mentioned information on bile acid interactions within the colon, it
is clear that more insight into the interactions between bile acids, secondary bile acids, and
soyasaponins could be valuable in understanding the chemopreventive properties of
soyasaponins and their metabolites, which in turn could possibly lead to the development of
tumor prevention strategies. These effects seem to be stemming from actions within the lumen
of the colon and on the mucosal cell membranes of the colon, it would be pertinent to address the
bioavailability, effect of colonic microflora and metabolism of soyasaponins, and possible
toxicity issues that may arise from a soyasaponin supplemented experimental diet.

Bioavailability and Metabolism of Soyasaponins
In earlier animal studies, combinations of DDMP and non-DDMP soyasaponins were fed
to mice, rats, and chicks [94, 95]. In these studies, saponins were found in the stomachs and
small intestines, while only the aglycone sapogenols and a very small amount of saponins were
found in the cecum and feces. This suggests that the sapogenols are the primary metabolites.
In a more recent study [75], soyasaponin I was incubated anaerobically with human fecal
microflora to investigate how soyasaponins were metabolized and also to identify the
metabolites. Over a 48 hr period, it was observed that as soyasaponin I decreased, soyasaponin
III increased, and at the end of the 48 hr period the remaining product was soyasapogenol B.
This follows a convincing pattern considering soyasaponin I has three sugars, soyasaponin III
has two sugars, and soyasapogenol B contains no sugars.
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A human feeding study conducted by Hu et al. [74] featured an extract containing a
mixture of approximately 435 µmol group B soyasaponins which was fed to a group of eight
women. Urine and fecal samples were collected and analyzed revealing no soyasaponins in the
urine or feces, but sapogenol B was found in the fecal material collected from the subjects. From
this study we are able to gain some understanding of the fate of ingested soyasaponins in
humans, but more detailed information from in vivo conditions is needed.
As part of the previous study by Hu et al., mucosal uptake and transepithelial kinetics of
soyasaponin I and soyasapogenol B were measured using the Caco-2 cell monolayer model. The
results of this study show that the mucosal transfer rates and apical to basolateral absorptions of
soyasaponin I and soyasapogenol B were low.

Soyasaponin I showed a saturable and

concentration-independent transport and cell-uptake rate, however, soyasapogenol B was taken
up by the Caco-2 cells in a concentration-dependent manner. Results of this study confirm the
hypothesis of other studies that soyasaponins and their sapogenol have low absorbability in
human intestinal cells, are metabolized to the aglycone form by gut microflora, and are excreted
in the feces.

Toxicity
An animal toxicity study was performed by MacDonald et al., [77] in which young
C57blackJ mice were fed increasing amounts of purified soyasaponins (0-3% by weight) for 4
weeks. The treatment had no negative effects on body weight gain, organ weight, or colonmucosal parameters.

The before mentioned study by Hu et al., [74] demonstrated that

soyasaponins have poor absorption in the human body and are metabolized by the microflora
within the gastrointestinal tract and are excreted in the feces. Also, the safety of soyasaponins in
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feedstuffs [96] and commonly used food items [97] has been established. In addition to their
safety, the quantification of soyasaponins in commonly used soy foods has been determined as
well [98].

20

Chapter III. Materials and Methods
Soyasaponin I, III, and Soyasapogenol B Preparation
Soyasaponins I and III were isolated from soybeans that were grown as part of a study
evaluating elicitor spray on soybeans and soyasaponin content at the University of Arkansas, as
well as from a mixture of soyasaponins that was generously provided by Organic Technologies
(Coshocton, OH). Total group B soyasaponins were extracted from whole soybeans by first
coarsely grinding with a spice grinder to break the seeds, and then finely ground using a cyclone
mill (UDY Cyclone Lab Sample Mill Model 3010-030), after which the ground soybean meal
was passed through a 60 mesh sieve. The ground soybean meal was defatted using n-hexane in a
Soxhlet apparatus. The remaining defatted soybean meal was then extracted for 2.5 hours with
70% ethanol in an Erlenmeyer flask on an orbital shaker at room temperature. Afterwards, the
extraction mixture was filtered through Whatman no. 1 filter paper and collected in a round
bottom flask. The soybean extract was rotary evaporated at 30°C. The remaining syrup-like
residue was resuspended in water and freeze dried. HPLC analysis of the resulting soybean
extract showed 10 different soyasaponins and there were no interfering isoflavones present. The
soybean extract was fractionated via semi-prep HPLC as well as used as the starting material for
alkaline hydrolysis.
Alkaline hydrolysis was used to convert DDMP-conjugated soyasaponins into nonDDMP soyasaponins, which was necessary for acquiring soyasaponins I and III. A modified
method from Zhang et al. [99] was used for the alkaline hydrolysis, beginning with 100 mg of
crude soyasaponin extract which was suspended in anhydrous methanol containing 5% NaOH
(v/v). The mixture was placed in a closed reaction vessel and placed in an 80°C water bath for
30 minutes. After cooling, the reaction mixture was neutralized with concentrated HCl, diluted
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with D.I. water to 50% methanol, and loaded on a preconditioned 10g C18 Sep-Pak column
(Grace Davison, Deerfield, IL).

The column was washed with water (100 ml) and the

hydrolyzed mixture was then eluted with 80% methanol (50ml) and collected to be dried.
Finally, the column was rinsed with 100% methanol to remove any remaining non-polar
compounds; the column could then be reused. After rotary evaporation and subsequent freeze
drying, the hydrolysis powder was subjected to HPLC analysis for confirmation of degree of
hydrolysis and soyasaponins present. Soyasaponins V, I, II, and III were obtained in this manner
via fractionation by semi-prep HPLC (Shimadzu Prominence CBM-20 Communications Bus
Module, SPD-M20A Diode Array Detector, LC-20AB Liquis Chromatograph Pump) utilizing a
reverse phase C18 YMC-Pack ODS-AM 250 x 10mm I.D. column.
The harsh conditions provided by 3N HCl and a boiling water bath are sufficient to
cleave all carbohydrate moieties from the triterpene unit, but leave the aglycone 5-ring structure
intact, and thus soyasapogenol B will be produced by acid hydrolysis using a modified method
from Hu et al. [74]. 250 mg of group B soyasaponins provided by Organic Technologies
(Coshocton, OH) were refluxed with 100 ml of 3N HCl in a boiling water bath for 45 minutes.
The reaction mixture was quickly cooled and neutralized with 10N NaOH. The neutralization
process resulted in salt forming due to the interaction of HCL + NaOH → NaCl + H2O. The
reaction mixture was desalted and the remaining sugars were removed by loading the mixture on
a preconditioned 10g C18 Sep-Pak column (Grace Davison, Deerfield, IL) and washed with
increasing percentages of methanol. The soyasapogenol B fraction is eluted using 200ml of
100% methanol. The fraction was rotary evaporated at 30°C, suspended in water, and then
transferred to another flask to be freeze dried. The resulting powder is then ready to be further
purified via semi-prep HPLC (Shimadzu Prominence CBM-20 Communications Bus Module,
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SPD-M20A Diode Array Detector, LC-20AB Liquis Chromatograph Pump) utilizing a reverse
phase C18 YMC-Pack ODS-AM 250 x 10mm I.D. column.

Cell Culture
Caco-2 human colon cancer cells were purchased from the American Type Culture
Collection (ATCC, Rockville, MD) at passage number 18 and cultured in Dulbecco's modified
eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% Non-essential
amino acids, 2% antibiotic-antimicotic, and incubated at 37°C in a humidified 5% CO2
atmosphere. All media components and reagents were obtained from Gibco® through Life
Technologies (Carlsbad, CA).

Cell Viability Assay
Cells at passage numbers 30-31 were used for the following proliferation assays. Cellular
proliferation and viability were measured using the CellTiter 96® AQueous One Solution Cell
Proliferation Assay (Promega Corp. Madison, WI). This assay is a colorimetric method for
determining the number of viable cells in proliferation or cytotoxicity assays. The CellTiter
reagent

contains

a

novel

tetrazolium

compound

[3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron
coupling reagent (phenazine ethosulfate; PES).
The MTS tetrazolium compound is bio-reduced by living cells into a colored formazan
product which is soluble in culture medium. The assays are performed by adding a small amount
of the CellTiter reagent directly to culture wells in a 96 well plate, incubating for 1-4 hours
(depending on the metabolic rate of your cells), and then recording the absorbance at 490nm with
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a plate reader (Synergy HT Multi-Mode Microplate Reader, BioTek Instruments, Inc., Winooski,
VT). The quantity of formazan product measured by the absorbance at 490nm is directly
proportional to the number of living cells in culture, as seen in Figure 3.
To perform this assay, (2 x 103) Caco-2 cells in 100µl of DMEM containing 10% fetal
bovine serum were seeded in the wells of a 96 well plate and incubated at 37°C and 5% CO2.
After stable attachment (48 hrs) media was removed and replaced with test media containing
soyasaponins I, III, and sapogenol B at concentrations of 0, 300, 600, and 900 ppm.
Viability measurements were made at 4 different time points: 0, 24, 48, and 72 hrs. this
was accomplished by adding 20µl of CellTiter reagent directly to the wells containing cells as
well as wells containing only the test media (to be used as a sample control) and incubating for 4
hours before measuring the absorbance at 490nm. After all absorbance readings had been made,
corrections were made for the background absorbance of the control media as well as the sample
control media which contained soyasaponins.

Absorbances were then converted into cell

numbers using an equation from the Caco-2 cell standard curve completed earlier in which a
serial dilution of cells was prepared in triplicate in a 96 well plate which ranged from 350 cells
per ml to 70,000 cells per ml. After the dilution was complete, CellTiter reagent was added and
absorbances were recorded after 4 hours. After absorbances were converted into cell numbers,
cell growth curves were then plotted.

Light Microscopy of Cells
Cell morphology was observed using a Nikon Eclipse E400 light microscope with Nikon
Camera Head DS-Fi1. Cells from passage number 41 were used to visualize morphology
changes. After 72 hours of treatment with soyasaponin I, III, or soyasapogenol B, cells were
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harvested and an aliquot was taken from the cell suspension. A portion of the aliquot was then
stained with trypan blue dye to determine viable from non-viable cells and also to provide
contrast. 10µl of the aliquot was then pipetted onto a slide and covered with a cover-slip. The
prepared slides were viewed under low power magnification until an acceptable cell was
identified. The cell of interest was then viewed under higher power (400x). Using the Nikon
camera software, contrast and color was adjusted to provide the best possible image, after which,
a still shot was taken and saved for later viewing.

PKC Assay
Cells at passage numbers 39-40 were used for PKC enzyme activity assays. PKC activity
was determined with the PepTag® Non-Radioactive PKC assay kit (Promega Corp. Madison,
WI). The PepTag® Assay utilizes a brightly colored fluorescent peptide that it highly specific for
PKC, which phosphorylates the PKC peptide, thus changing its net charge from +1 to -1. The
change in net charge of the substrate allows the phosphorylated and non-phosphorylated versions
of the substrate to be rapidly separated on an agarose gel. The color of the PepTag® Peptide
substrate is imparted by the addition of a dye molecule, which allows for easy visualization of
the bands during the electrophoresis process. After electrophoresis, the bands can be excised, resolubilized, and quantified by reading their absorption on a plate reader at 570nm.
For this assay, 5 x 106 Caco-2 cells were seeded in a 75cm2 flask.

After stable

attachment, media was removed and replaced with test media containing 300, 600, and 900ppm
of soyasaponins I and III and 50, 100, and 150ppm of sapogenol B, as well as media containing
no soyasaponins or soyasapogenol B. All media except that of the negative control contained
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12-O-tetradecanoyl phorbol 13 acetate (TPA) (100ng/ml), a known PKC stimulator. The cells
were then incubated for 72 hrs at 37°C and 5% CO2.
After the incubation time was over, all media was collected, cells were rinsed with
phosphate-buffered saline (PBS), the cells were trypsinized, removed from the flask, and the
flask was rinsed again with PBS to collect all remaining cells. To pelletize the cells, the mixture
was centrifuged and all supernatant was completely removed. The cells were then suspended in
0.5ml of cold PKC extraction buffer (Table 2) and then homogenized by using multiple freeze
thaw cycles and a probe sonicator (XL-2000 Q Sonica, LLC, Newton, CT). The cell lysate was
then centrifuged for 5 minutes at 4°C, 14,000 x g in a microcentrifuge. The supernatant was
passed over a 1ml column of Whatman diethylaminoethyl cellulose that had already been
preconditioned with PKC extraction buffer.

The column was washed with 5ml of PKC

extraction buffer. The PKC-containing fraction was eluted using 5 ml of PKC extraction buffer
containing 200mM NaCl.
For each sample, the PepTag® Reaction 5X buffer, PepTag® C1 peptide, PKC Activator
5X solution, and DI water was added to a 0.5ml microcentrifuge tube and kept on ice until the
sample was ready to be added. At time zero, the tubes were removed from the ice and incubated
in a 30°C water bath for 2 minutes. Then, the sample was added and incubated for another 30
minutes at 30°C. The reaction was stopped by placing the tubes in a boiling water bath for 10
minutes. The samples were stored at 4°C in the dark until they were ready to be loaded on the
gel.
A 0.8% agarose gel was prepared using 50mM Tris-HCl pH 8.0. The solution was heated
until the agarose was completely dissolved and was allowed to cool to approximately 60°C
before pouring into the gel tray. Only one comb was used and it was placed in the middle of the
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gel. The gel was allowed to solidify for 30 minutes. The horizontal gel apparatus was assembled
according to the manufacturer’s specifications.
After the gel had solidified, it was placed in the electrophoresis chamber and the comb
was gently removed. 50mM Tris-HCl (pH 8.0) was poured over the gel until the gel was
covered completely. Before loading the samples, 1µl of 80% glycerol was added to each sample
to ensure it stayed in the well. Immediately after the last sample was loaded, the gel was run at
100V for 15-18 minutes. Once the electrophoresis was complete, the gel was removed from the
chamber and photographed under UV light to provide for greater sensitivity.
Using a scalpel, the negatively charged bands were quickly excised to avoid diffusion.
The excised band was then placed into a 1.5ml microcentrifuge tube and heated at 95°C until the
gel slice was melted. 125µl of the hot agarose was pipetted into a tube containing 75µl of Gel
Solubilization Solution and 50µl of glacial acetic acid. The mixture was quickly vortexed and
transferred to a well in a 96-well plate. After all the samples had been transferred to the 96-well
plate, the absorbance was read at 570nm. The plate reader was blanked by using liquefied
agarose without PapTag® Peptide. The activity of PKC in the samples was then calculated using
the absorbances seen in the PKC positive control dilution assays.

Statistical Analysis
Data will be analyzed using Statistical Analysis System (Version 9.2; SAS Institute Inc.,
Cary, NC). Results will be analyzed using one-way analysis of variance using an alpha level of
0.05 followed by Fisher’s least significant difference (LSD) test. Data is presented as means ±
standard error of the mean (SEM).
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Chapter IV. Results
Soyasaponins I, III, and Soyasapogenol B inhibit proliferation of Caco-2 Cells.
Treatment of cultures of Caco-2 cells with soyasaponins I, III and soyasapogenol B
decreased cell proliferation in a time and concentration-dependent manner (Table 3, Figure 4, &
5). As early as 24 h after initiation of soyasapogenol B treatment, viable cell numbers were
significantly reduced by 14.7-62.4%, compared with the control, at concentrations of 100-150
ppm respectively (p<0.05) (Table 3). After 48 h of treatment, Soyasaponins I and III at all
concentrations reduced viable cell numbers by 9.6-34.6% (p<0.05) (Table 3). Similarly, after 72
h of soyasaponins I, III, and soyasapogenol B treatment viable cell numbers were significantly
reduced by 46.3-94.3%, compared with the control (p<0.05) (Table 3).

Light Microscopy
Figure 6 shows the light microscope observations of Caco-2 cells treated with 0, 300,
600, and 900 ppm of soyasaponins I and III (Figure 6. (b) & (c)) as well as 50, 100, and 150
ppm of soyasapogenol B (Figure 6. (d)). When the dose of soyasaponins increased, the surface
of Caco-2 cells became rougher, and the cell shape changed from round to irregular. As the dose
of soyasaponin I and III reached 900 ppm, breaks were seen on the surface of Caco-2 cells. At
the highest concentrations of soyasapogenol B, complete deformation of Caco-2 cells was
observed (Figure 6 (d)).

PKC Assay
Expression of the proliferation enzyme PKC was decreased in cells treated with
soyasaponins I, III, and soyasapogenol B (Table 4). Soyasaponin I reduced PKC expression in a
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dose-dependent manner, ranging from 9.0-27.3% reduction in PKC activity compared to the
control (p<0.05). Soyasaponin III also reduced PKC activity in a dose-dependent manner.
Reductions of 18.2-40.0% were seen in the soyasaponin III group (p<0.05) . The soyasapogenol
B group showed reductions in PKC ranging between 56.4-70.9%. The 100 and 150 ppm groups
showed significantly greater reductions than the 50 ppm group (p<0.05), but 150 ppm was not
significantly greater than the 100 ppm group.
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Chapter V. Discussion
Numerous epidemiological and experimental studies have suggested that soy contains
several bioactive phytochemicals. However, the possible mechanisms of their effects are not
fully understood. Confusion from different animal models, cell lines, and test materials have
further complicated the task of identifying what soy phytochemicals are responsible for the
health effects linked with soy consumption.
In the present study, the effects of the predominant soyasaponin in heat treated soy
products (soyasaponin I) as well as its two primary metabolites (soyasaponin III and
soyasapogenol B) were tested to evaluate their effect on cell growth, cell morphology changes,
and proliferation-related enzyme activity of Caco-2 human colon cancer cells. Soyasaponins I,
III, and soyasapogenol B effectively inhibited the growth rate and survival of human colon
cancer cells, altered cell morphology, and inhibited the TPA-stimulated PKC activity in a dosedependent manner.
Soyasaponins I, III and soyasapogenol B decreased cell proliferation in human colon
cancer cells in a time and concentration-dependent manner (Table 3). Cell proliferation and
viability data from this study compare favorably with previous research [65-68, 72]. However,
these studies utilized different cell lines HT-29 and HCT-15, different soyasaponin mixtures, and
concentrations. When comparing the data of these studies, it is important to look at the growth
curves of both the control cells and the treatment cells. Control cells display an exponential
growth curve, but depending on the cell line, the slope of that line may vary in steepness. The
doubling time of HT-29 cells and HCT-15 cells vary, but is approximately 24 hrs. Caco-2 cells
on the other hand are metabolically slower and double approximately every 62 hours.
Depending on the study, cell proliferation and viability studies used different methods. Some
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studies plated a specific density of cells in 35mm cell culture plates and determined cell count
and viability using a hemocytometer and trypan blue [64-67], while others used 96 well plates
and a chemical reagent which would be bio-reduced to form a colored product which could be
quantified using a plate reader [63,73]. Either method produces similar growth curve patterns.
So, even while all the control growth curves are not identical, they follow an exponential pattern.
Treatment-cell growth curves vary from study to study, but they too follow a similar pattern, in
that they always respond in a dose-dependent manner and are generally similar to the negative
control curve, but differ in steepness. An example of this can be seen in figure 7 [66]. In the
present study, the cell growth curves of the treatment groups, up to 48 hours, resemble those of
the before mentioned research [66]. Where this study varies from previous research is that
depending on the treatment group, the growth curves do not continue upwards after 48 hours.
Depending on treatment group, the cells plateau after 24 hours or begin to die off after 48 hours
eventually returning to near 0 hour cell numbers after 72 hours. The soyasapogenol B data tells a
somewhat different story because of its increased bioactivity. Soyasapogenol B at 50 and 100
ppm begin to follow the growth curves of previous research up to 24 hours, but after which cell
proliferation stops and cell viability drops off dramatically leading up to the 48 and 72 hour time
points.
Comparison with other studies utilizing mixtures of soyasaponins shows that the purified
soyasaponins used in this study were more effective in reducing cell growth at lower
concentrations. Tsai et al. [63] reduced cell growth by 27% at 72 hours when treated with 600
ppm of soyasaponins compared with control cells. However, the 300 ppm soyasaponin group
was not significantly different from the control cells. In the current study, soyasaponins I and III
at 300 and 600 ppm reduced cell growth by 46-55% at 72 hours (Table 3). Three other studies
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[64, 66, 67] which utilized a mixture of soyasaponins demonstrated that cell growth could be
significantly reduced by 150, 300, and 600 ppm of soyasaponins after 48 and 72 hours, but the
percent reduction in cell growth compared to the control cells was not listed. Even though the
percent reduction in cell growth was not listed in these studies, it is clear when looking at the cell
growth curves that these soyasaponin mixtures did not have the same affect that the purified
soyasaponins in this study did. When reaching the 48 and 72 hour time points in the previously
listed studies, cell growth curves were still progressing steadily upwards, but in the current study,
cell growth curves were already plateauing (48 hours) or decreasing (72 hours) (Figure 4. a &
b).
In the only other study that utilized individual soyasaponins [73], soyasaponin I, III and
soyasapogenol B were utilized at 6, 12, 25, and 50 ppm. The study also utilized a group B
soyasaponin mixture at those same concentrations. After 72 hours of treatment, the group B
mixture and soyasaponin I groups had no effect on cell growth. Soyasaponin III at its highest
concentration reduced cell growth by approximately 25%, it’s difficult to make a comparison to
this study, but soyasaponin III at 300 ppm reduced cell growth by 49% (Table 3). This is a
higher percentage, but also a higher concentration. Soyasapogenol B at 50 ppm reduced cell
growth by approximately 90-95% in the study mentioned above. The current study reduced cell
growth by 87% (Table 3), which is similar in comparison to the 90-95% reduction seen in the
other study. Gurfinkel et al. [73] demonstrated that the soyasaponin mixture and soyasaponin I
did not have an effect, but soyasaponin III (with fewer sugars) and soyasapogenol B (no sugars)
decreased cell growth. Evidence from Gurfinkel et al. [73] and the current study indicate that
differences in soyasaponin lipophilicity have a significant effect on bioactivity and resulting
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cancer cell growth. All this lends to the hypothesis that with greater lipophilicity there is also
greater bioactivity.
By viewing under a microscope, it became evident that when treated with increasing
concentrations of soyasaponins and soyasapogenol B, cell membranes became more rough and
irregular.

At the highest concentrations of soyasaponin and soyasapogenol B complete

deformation of Caco-2 cells was observed (Figure 6). In the study by Tsai et al, [63] as
concentrations of soyasaponins increased, the surface of the HT-29 cells became more rough and
irregular leading up to 600 ppm. At 1200 ppm, breaks were seen on the surface of the cells, and
at 2400 ppm, complete deformation of the HT-29 cells was observed. The changes in cell
morphology are suggestive that soyasaponins may be binding to or inserting into the cell
membrane. This is particularly relevant because the membranes of some cancer cells contain
more cholesterol than normal cell membranes. Because of this, it is also likely that soyasaponins
bind more to cancer cells, and thus in the intestine, soyasaponins can bind to the mucosal cell
membrane, change its physiology, and as a result reduce cancerous cell growth. A relationship
between cell morphology and increased lipophilicity of soyasaponins and soyasapogenol B was
observed in this study. Morphological changes observed through microscopy of cells indicate
that as lipophilicity increases, cell morphology and cell membrane integrity become more
compromised. Cell membranes become rough and irregular with treatment of soyasaponins I
and III. With treatment of soyasapogenol B, cell membranes were irregular and eventually
deformed to the point where the membranes are no longer intact and the cell was completely
deformed.
PKC is one of the markers for cell proliferation and its activity increases as the cells
undergo the proliferation process. As shown in this study, the addition of soyasaponins I, III,
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and soyasapogenol B to the cell culture media effectively reduced the expression of PKC in
colon cancer cells. Previous research [64-66] has shown similar results when using crude
mixtures of group B soyasaponins and HT-29 colon cancer cells. Kim et al., [65] demonstrated
that 600 ppm soyasaponins significantly reduced PKC expression after 72 hours. Treatment with
150 and 300 ppm did not significantly reduce PKC expression. In the study by Oh et al., [66]
PKC expression was significantly reduced by 300 and 600 ppm soyasaponin treatment.
However, there was no dose dependent effect. The reduction in PKC activity in the 600 ppm
group was not significantly greater than the 300 ppm group, 21.4 and 20% respectively.
In this study, there was a dose dependent effect seen in the soyasaponin I group. For the
300, 600, and 900 ppm groups, PKC activity was reduced by 9.1, 16.4, and 27.3% respectively
(Table 4). Soyasaponin III followed a similar pattern, and reductions for this group are as
follows: 18.2, 32.7, and 40.0%. Depending on the soyasaponin, the percent reductions in PKC
activity of this study are close to those of the previously mentioned studies [63-65] which used
soyasaponin mixtures. Soyasaponin I reduction was less than the reported values in these studies
when used at the same concentrations, but soyasaponin III had a greater reduction at the 600 ppm
concentration compared to mixtures of soyasaponins at that same concentration.
Initially, it appeared that the soyasapogenol B group had reduced the PKC activity of the
cells by 56.4, 65.5, and 70.9% (Table 4). However, because of its increased bioactivity, after 72
hours cell viability was extremely low, therefore, the measured reduction in PKC activity may
not have been due to reduced expression of the protein by the cells, but rather because the cells
were no longer alive to produce the protein.
Previous report has indicated that soyasaponins possess surface-active properties [67].
Transmission electron microscopy imaging indicates that soyasaponins induced the formation of
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vacuoles and deformations in plasma and nuclear membranes of cells [72]. By binding to or
inserting themselves into the cell membrane, they are able to disrupt normal cell function, which
appears to be the case with PKC. Previous studies have suggested that the disruption by the
soyasaponins somewhat modulates the translocation of PKC from the cytosol to the cell
membrane [65, 66], thus reducing its expression.

As mentioned earlier, soyasaponin-cell

membrane interactions appear to be the key mechanism by which soyasaponins elicit their
effects. Proliferation and viability data, microscopy results, and PKC activity from this study all
indicate that the bioactivity of soyasaponins and soyasapogenol B are directly related to their
molecular structure and more importantly their lipophilicity. The differences in bioactivity are
likely due to the fact that with increases in lipophilicity, there is more soyasaponin/
soyasapogenol B interaction with the cancer cell membranes, which are rich in phospholipids
and cholesterol.
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Chapter VI. Conclusion
The predominant soyasaponin in heat treated soy products, soyasaponin I, is metabolized
first into soyasaponin III and finally into soyasapogenol B by colonic microflora. In summary,
cell proliferation and PKC activity were reduced in a dose dependent manner when treated with
these phytochemicals. Data from proliferation and PKC assays as well as morphological analysis
indicates that the suppression of cell growth and disruption of cell membrane integrity is
intensified with increases in lipophilicity of the soyasaponins and soyasapogenol B, meaning that
soyasapogenol B is greater than soyasaponin III which is greater than soyasaponin I. The results
of this study indicate that the predominant soyasaponin in heat treated soy products and its two
metabolites, at physiologically relevant doses, can suppress colon cancer growth. These findings
suggest that purified soyasaponins and soyasapogenol B may be a colon cancer suppressive
component of soy which warrants further examination as a potential nutraceutical or functional
food.
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Appendix
Figure 3. CellTiter 96® AQueous One Solution Caco-2 Cell Standard Curve
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Table 2. PKC Extraction Buffer
Ingredients

Final Concentration

Tris-HCL (pH 7.4)

25mM

EDTA

0.5mM

EGTA

0.5mM

Triton® X-100

0.05%

β-mercaptoethanol

10mM

Leupeptin

1µg/ml

Aprotinin
1µg/ml
0.5ml Stock solution (100mM PMSF in 100% EtOH) per
100ml of PKC extraction buffer added just before use.
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Figure 4. (a) Soyasaponin I effects on CaCo-2 cell proliferation
9
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24
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Different concentrations of Soyasaponin I at each incubation time were compared against the
negative control using Dunnett’s test. Points marked with (*) represent significant differences at
the P<0.05 level.
(b) Soyasaponin III effects on Caco-2 cell proliferation
9
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Different concentrations of Soyasaponin III at each incubation time were compared against the
negative control using Dunnett’s test. Points marked with (*) represent significant differences (p
< 0.05)
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Figure 5. (a) Soyasapogenol B effects on Caco-2 cell proliferation
9
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(b) Soyasapogenol B effects on Caco-2 cell proliferation
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Different concentrations of Soyasapogenol B at each incubation time were compared against the
Negative Control using Dunnett’s test. Points marked with (*) represent significant differences
(p < 0.05)
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Table 3.
Soyasaponin I, III, and soyasapogenol B Percent Reduction in Cell Viability

Treatment
Soyasaponin I

Conc.
(ppm)
300
600
900

Soyasaponin III

Soyasapogenol B

24 Hours

48 Hours

72 hours

Percent
SEM
Reduction

Percent
SEM
Reduction

Percent
SEM
Reduction

0.1
0.5
1.1

300

0.5

600

5.8

a

900

0.23
0.23
0.40
0.23

9.6a
b

21.2

c

27.5

a

13.0

1.45

46.3a

1.80

0.95

b

2.47

d

0.14

a

0.28

c

0.78
0.41

52.3
60.1

48.5

0.15

21.2

b

1.00

55.2

0.15

5.8a

0.31

34.6d

1.57

65.3e

1.54

50

0.3

0.12

67.2e

1.14

87.2f

0.75

100

14.7b

6.87

73.3f

1.90

88.4f

0.32

150

62.4c

0.99

87.9g

0.43

94.3g

0.29

Data represents the percent reduction (%) compared with negative control and the standard error
of the mean (SEM) (n = 3). Values in a column without common superscripts are significantly
different (p < 0.05).
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Figure 6. Morphological effects of treatment with different concentrations of Soyasaponin I,
I III,
and soyasapogenol B.
(a) Untreated Caco-2 cell

(b) Soyasaponin I treatment for 72 hours

(i) 300ppm

(ii) 600
00 ppm

(iii) 900 ppm

(c) Soyasaponin III treatment for 72 hours

(i) 300ppm

(ii) 600
00 ppm

(iii) 900 ppm

(d) Soyasapogenol B treatment for 72 hours

(i) 50 ppm

(ii) 100 ppm

(iii) 150 ppm
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Figure 7. Example of typical growth curves in a proliferation assay. Figure taken from Oh et.al.,
2001 [66]
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Table 4. Reduction of PKC by soyasaponins I, III, and sapogenol B
Treatment
Soyasaponin I

Soyasaponin III

Conc.
(ppm)

Percent Reduction
(%)

SEM

300

9.1a

1.82

600

16.4b

1.82

900

c

1.82

b

3.15

c

1.82

d

3.15

e

3.15

f

1.82

27.3

300

18.2

600

32.7

900
Soyasapogenol B

40.0

50

56.4

100

65.5

1.82
150
70.9f
Data represents the percent reduction (%) compared with control (cells+100ng/ml TPA) and the
standard error of the mean (SEM) (n = 3). Values in a column without common superscripts are
significantly different (p < 0.05).
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